Production and Evaluation of In-vitro and In-vivo Effects of P28-IL24, a Promising Anti-breast Cancer Fusion Protein

Published on Aug 24, 2021in International Journal of Peptide Research and Therapeutics1.5
· DOI :10.1007/S10989-021-10275-Z
Reza Ghavimi5
Estimated H-index: 5
(IUMS: Isfahan University of Medical Sciences),
Vajihe Akbari12
Estimated H-index: 12
(IUMS: Isfahan University of Medical Sciences),
Ali Jahanian-Najafabadi15
Estimated H-index: 15
(IUMS: Isfahan University of Medical Sciences)
Sources
Abstract
Interleukin-24 (IL-24) is known to selectively induce apoptosis in cancer cells through endoplasmic reticulum (ER) stress. However, this protein alone is unable to enter cells and consequently it is not able to inhibit cell proliferation. In this study, we developed a novel recombinant chimeric protein containing IL-24 which is linked to P28, a cancer specific cell-penetrating peptide and P53 stabilizer, to target IL-24 into breast cancer cells. After design, expression and purification of the P28-IL-24 fusion protein and IL-24 as control, specific and non-specific cytolethal effects of this fusion protein were evaluated in-vitro and in-vivo. Cell proliferation assay and cell death mechanism analysis carried out by MTT and flow cytometry, respectively. Afterward, anti-tumor effects of P28-IL-24 in animal model were investigated by hematoxylin and eosin (H&E) staining and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay, respectively. Results showed inhibitory effects on proliferation of MCF-7 and MDA-MB-231 cancer cells by the P28-IL-24 protein. However, HUVEC cells were affected by the fusion protein just at 1.8 µg/ml concentration. In addition, p28-IL-24 showed to induce apoptosis in the mentioned cell lines. Moreover, treatment of inbred Balb/C mice bearing syngenic 4T1 tumor cells with the p28-IL-24 reduced tumor size within the study period (p < 0.05). H&E staining and TUNEL assay, revealed that this tumor growth suppression was associated with increase in necrotic and apoptotic cells. Taken together, the findings of the current study suggest that the chimeric protein p28-IL-24 can serve as a potent candidate for further preclinical evaluations.
📖 Papers frequently viewed together
36 Citations
20081.71Tumori
1 Author (Shan Bao-en)
References48
Newest
#1Ali Ghasemi (Semnan University)
#2Reza Ghavimi (IUMS: Isfahan University of Medical Sciences)H-Index: 5
Last. Mohsen Mohammadi (Bushehr University of Medical Sciences)H-Index: 8
view all 5 authors...
Breast cancer is one of the well-known non-cutaneous cancers among women worldwide. In the present study, we have characterized the anti-cancer activity of Moronecidin-like peptide derived from the Hippocampus comes in comparison with a well-known antimicrobial peptide (AMP), Piscidin. Evaluation of the cytotoxic activity of the peptides against 4T1 cancer cells and bone marrow-derived dendritic cells (BMDCs) using MTT assay and flow cytometry demonstrated a concentration-dependent cytotoxicity ...
1 CitationsSource
#1Wei-wei Chen (ZJNU: Zhejiang Chinese Medical University)
#2Hong-rui Zhang (ZJNU: Zhejiang Chinese Medical University)
Last. Zhen-hong Zhu (ZJNU: Zhejiang Chinese Medical University)
view all 7 authors...
MAP30 (Momordica antiviral protein 30kD) is a single-chain Ⅰ-type ribosome inactivating protein with a variety of biological activities, including anti-tumor ability. It was reported that MAP30 would serve as a novel and relatively safe agent for prophylaxis and treatment of liver cancer. To determine whether adding two tumor targeting peptides could improve the antitumour activities of MAP30, we genetically modified MAP30 with an RGD motif and a EGFRi motif, which is a ligand with high affinity...
1 CitationsSource
#1Reza Ghavimi (IUMS: Isfahan University of Medical Sciences)H-Index: 5
#2Elmira Mohammadi (IUMS: Isfahan University of Medical Sciences)H-Index: 4
Last. Ali Jahanian-Najafabadi (IUMS: Isfahan University of Medical Sciences)H-Index: 15
view all 5 authors...
Background and purpose: An anticancer peptide P28, has shown to be cytolethal on various cancer cells including breast cancer. Moreover, p28 can be also used as a targeting moiety in the structure of fusion proteins. IL-24 (or its truncated form, M4) is a cytokine with anticancer activity against a wide range of tumor cells. We aimed at production of a fusion protein consisted of p28 and either IL-24 or M4 to target breast cancer. However, selection of a proper linker to join the two moieties wi...
2 CitationsSource
#1Fan Huang (HBUT: Hubei University of Technology)H-Index: 1
#2Qianhui Shu (HBUT: Hubei University of Technology)H-Index: 1
Last. Meng Gao (HBUT: Hubei University of Technology)H-Index: 4
view all 7 authors...
Cancers are a great threat to humans. In cancer therapy, surgical removal of the tumor combined with radiotherapy and chemotherapy is the most routine treatment procedure and usually the most effective. However, radiotherapy and chemotherapy drugs that kill cancer cells efficiently also kill normal cells, thus exhibiting large side effects. Cancer-targeted drugs, which aim to specifically recognize proteins or signaling pathways associated with tumor proliferation and migration, have achieved ma...
4 CitationsSource
#1Marjan Pourhadi (IUMS: Isfahan University of Medical Sciences)H-Index: 1
#2Fahimeh Jamalzade (IUMS: Isfahan University of Medical Sciences)H-Index: 1
Last. Fatemeh Shafiee (IUMS: Isfahan University of Medical Sciences)H-Index: 5
view all 4 authors...
Interleukin (IL) 24 is a pro-inflammatory and tumor suppressor cytokine capable of inducing selective apoptosis in various cancer cells. BR2, on the other hand, is an anti-microbial peptide with selective penetrability to the cancer cells. In this study, we aimed to produce and purify a fusion protein containing IL24 as the toxic moiety fused to BR2, as targeting moiety, and then to evaluate its cytotoxic activities. For this purpose, the coding sequence of IL24-BR2 fusion protein and IL24 were ...
7 CitationsSource
#1Li Liu (Northwest University (United States))H-Index: 1
#2Jiabin Ma (ZSTU: Zhejiang Sci-Tech University)H-Index: 1
Last. Yahui Wei (Northwest University (United States))H-Index: 1
view all 6 authors...
BACKGROUND: Acute promyelocytic leukaemia (APL) is a clonal disease arising by hematopoietic stem cell (HSC), which characterized by inappropriate proliferation/differentiation or survival of immature myeloid progenitors. Oncolytic adenoviruses have been under widespread investigation as anticancer agents. Recently, our data suggested that tumor cells were cured by AdCN205-IL-24, an adenovirus serotype 5-based conditionally replicating adenovirus expressing IL-24 after infection. METHODS: In thi...
5 CitationsSource
#1Jie YangH-Index: 8
#2Hong YinH-Index: 4
Last. Junnian ZhengH-Index: 33
view all 7 authors...
Abstract The interleukin-24 (IL-24), a member of the IL-10–related cytokine gene family, is well known for its tumor suppressor activity in a broad spectrum of human tumors without damaging normal cells. However, poor tumor penetration remains a key problem for the efficacy of IL-24 as a treatment. iRGD is a novel tumor-specific peptide with unique tumor-penetrating and cell-internalizing properties. To enhance the tumor-penetrating and antitumor effects of IL-24, we engineered a recombinant pro...
5 CitationsSource
#1Ahmad NoeiH-Index: 1
Last. Meysam SoleimaniH-Index: 5
view all 3 authors...
Backgrounds Peptide-based drugs have shown promising results in overcoming the limitations of chemotherapeutic drugs by providing a targeted therapy approach to cancer. However, the response rate of targeted therapies is limited, in large part due to the intra- and inter-heterogeneity of tumors. Methods In this study, we engineered a novel chimeric protein composed of the p28 peptide as a tumor-homing killer peptide and apoptin as a killer peptide. We evaluated its cytotoxicity against MCF7 and ...
6 CitationsSource
One of the emerging therapeutic strategies for targeted therapy of cancer is the use of chimeric proteins. The p28 peptide has the ability of selective entrance and activating apoptosis in breast cancer cells. The NRC antimicrobial peptide showed cytotoxic activity on various breast cancer cell lines including drug-resistant cells and also on normal cells. Here we designed a chimeric protein consisting of these peptides to determine their targeted effects and to enhance their cytotoxic effects o...
7 CitationsSource
#1Ming YangH-Index: 5
#2Chunsheng Yang (Xuzhou Medical College)H-Index: 9
Last. Yan-Qun Liu (Xuzhou Medical College)H-Index: 11
view all 11 authors...
BACKGROUND: Temozolomide (TMZ) is widely used to treat melanoma; however, response rates to TMZ are low because of rapid and frequent resistance. Conditionally, replicative adenoviruses (CRAds) are an effective and promising approach. The receptor for adenovirus is coxsackie-adenovirus receptor (CAR), which is poorly expressed in most cells. However, CD46, which is the receptor of species B adenoviruses (Ads), is highly expressed in many cells. METHODS: We constructed CRAd F5/35-ZD55-IL-24, whic...
6 CitationsSource
Cited By0
Newest